| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFb126 |
| Uniprot No | Q9BYW3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-63aa |
| 氨基酸序列 | NWYVKKCLND VGICKKKCKP EEMHVKNGWA MCGKQRDCCV PAD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFb126重组蛋白的假设参考文献示例(注：文献为虚构，仅供示例参考)：
---
1. **文献名称**: *Structural and Functional Analysis of Recombinant DEFb126 in Sperm Motility*
**作者**: Tollner, T.L., et al.
**摘要**: 本研究通过重组表达人DEFb126蛋白，证实其通过结合精子表面糖基结构增强精子穿透宫颈黏液的能力，并解析了其C端结构域的关键作用。
2. **文献名称**: *DEFb126 Recombinant Protein: A Potential Biomarker for Male Infertility*
**作者**: Zhou, Y., et al.
**摘要**: 利用大肠杆菌系统表达DEFb126重组蛋白，发现其表达水平与男性精子质量下降显著相关，提示其可作为少弱精症的诊断标志物。
3. **文献名称**: *Antimicrobial Properties of Engineered DEFb126 Against Urogenital Pathogens*
**作者**: Bevins, C.L., & Ganz, T.
**摘要**: 通过体外实验证明，重组DEFb126对淋球菌和衣原体具有选择性抑菌活性，其机制可能与细胞膜穿孔作用有关。
4. **文献名称**: *Optimization of DEFb126 Recombinant Expression in Mammalian Cells*
**作者**: Smith, J.P., et al.
**摘要**: 开发了基于CHO细胞的高效DEFb126重组表达体系，通过糖基化修饰提升了蛋白稳定性，为未来临床应用奠定基础。
---
注：以上内容为模拟生成，实际文献需通过PubMed/Google Scholar等平台检索确认。
DEFb126. a member of the β-defensin family, is a small cysteine-rich cationic protein primarily studied for its roles in innate immunity and reproductive biology. Initially identified in the human epididymis, DEFb126 is notably expressed in the male reproductive tract and secreted into seminal fluid. It binds to sperm surfaces post-ejaculation, forming a protective glycoprotein coating critical for immune evasion during sperm transit through the female reproductive tract. This coating is hypothesized to shield sperm from innate immune responses, facilitate mucosal penetration, and enhance fertilization potential. Structural studies reveal its conserved disulfide-stabilized fold, characteristic of defensins, which mediates interactions with microbial membranes and host cells.
Interest in recombinant DEFb126 (rDEFb126) stems from its dual functional potential: antimicrobial activity against pathogens (e.g., bacteria, viruses) and immunomodulatory effects in fertility. However, native DEFb126 is challenging to isolate in quantity due to tissue-specific expression and low abundance. Recombinant production, typically using *E. coli* or mammalian expression systems (e.g., HEK293), enables scalable synthesis for functional studies. Purification often involves affinity chromatography and refolding steps to restore native conformation.
Research on rDEFb126 has clarified its molecular interactions, including binding to glycosaminoglycans on sperm and epithelial cells, and its pH-dependent antimicrobial mechanisms. Clinically, it is explored as a biomarker for male infertility, as reduced DEFb126 levels correlate with impaired sperm function. Additionally, synthetic analogs or recombinant forms are being evaluated for therapeutic applications, such as antimicrobial agents or fertility enhancers. Despite progress, challenges remain in optimizing its stability, bioavailability, and tissue-specific targeting. Current studies also investigate its role in non-reproductive contexts, such as airway mucosal immunity, expanding its potential biomedical relevance.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
